DDIs & Other Prescribing Issues, References

References Part III - Drug-drug Interactions and Other Prescribing Issues

American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019;67:674-94

Bettonte S, Berton M, Stader F, et al. Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modelling study, Clin Infect Dis 2023; 76(7):1225-1236

Brown K, Thomas D, McKenney K et al. Impact of splitting or crushing on the relative bioavailability of the darunavir/cobicistat/emtricitabine/tenofovir alafenamide single tablet regimen. Clin Pharmacol Dev 2019; 8(4):541-8

Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 2019; 74:1670-8
PK study showing that coadministration of TAF 25 mg qd with rifampicin results in lower exposure of TAF but intracellular tenofovir diphosphate levels are still 4.2 fold higher than those observed with TDF even without rifampicin

Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal H et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2009, 94(9):3132-54

Hiremath S, Blake PG, Yeung A, et al. Early experience with modified dose nirmatrelvir/ritonavir in dialysis patients with coronavirus disease 2019. Clin J Am Soc Nephrol 2023; 18(4):485-490

Hiremath S, McGuinty M, Argyropoulos C et al. Prescribing nirmatrelvir/ritonavir for COVID-19 in advanced CKD. Clin J Am Soc Nephrol 2022

Hocqueloux L, Lefeuvre S, Bois J, et al. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. J Antimicrob Chemother 2022; 78(1): 161-8

Hodge D, Back DJ, Gibbons S, et al. Pharmacokinetics and drug-drug interactions of intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 2021 Jul;60(7):835-853. doi: 10.1007/s40262-021-01005-1. Epub 2021 Apr 8
This review provides insight on the im administration of drugs and summarizes DDI profiles after oral and im administration of CAB and RPV

O’Mahony, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people. Age and Ageing 2015;44:213- 218

Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol (Oxf). 2015, 83(5):597-606

Orkin C et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virological failure over 152 weeks. International Congress on Drug Therapy in HIV Infection (HIV Glasgow) 2022, abstract O44
This analysis pooled data from the ATLAS, FLAIR and ATLAS-2M studies to determine factors that can be used to identify people with HIV at higher risk of experiencing failure of injectable treatment with cabotegravir and rilpivirine

Roskam-Kwint M, Bollen P, Colbers A, et al. Crushing of dolutegravir fixed dose combination tablets increases dolutegravir exposure. J Antimicrob Chemother 2018; 73(9):2430-2334

Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. Department of Family & Community Medicine, University of California, 2016

Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, London, 2013, Document CR181

Age Ageing 2015. Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, London, 2013, Document CR181 O’Mahony D et al.


Primary health Tasmania. A guide to deprescribing, available at www.primaryhealthtas.com.au

The Renal Drug Handbook. 5th ed. Boca Raton:CRC Press; 2019 Ashley C, Dunleavy A, editors